ライフサイエンスコーパス: vitreoretinal

1 na and we show that PtchlacZ+/- mice exhibit vitreoretinal abnormalities resembling those found in BC

2 ill be useful in investigating the effect of vitreoretinal adhesion on ocular hemorrhage caused by in

3 erlie vitreous liquefaction and weakening of vitreoretinal adhesion.

4 elp in resolution of the inflammation-driven vitreoretinal alterations, but ischemia of the deep reti

5 T is highly sensitive to visualize posterior vitreoretinal and choroidal structures into a single ful

6 The societal costs associated with vitreoretinal and other ophthalmic interventions include

7 Many vitreoretinal and other ophthalmologic interventions con

8 e following conditions: continuous posterior vitreoretinal attachment (PVA), vitreomacular adhesion (

9 Inclusion criteria were complete vitreoretinal attachment, no ocular pathology other than

10 2 residents, 6 vitreoretinal fellows, and 4 vitreoretinal attending physicians.

11 Primary vitreoretinal B-cell lymphoma and uveitis might be chara

12 authors speculate that the integrity of the vitreoretinal border is an important factor in preventin

13 January 2009 to December 2014, at 4 tertiary vitreoretinal centers in Italy were enrolled.

14 halmic data and operative information from 3 vitreoretinal centers were entered prospectively into an

15 ied 144 eyes of 72 consecutive patients in a vitreoretinal clinical practice, reviewing multimodal im

16 Vitreoretinal clinical practice.

17 In 37 patients, 65 eyes with CSC from 2 vitreoretinal clinical practices were imaged using ultra

18 This cohort study included data from all 14 vitreoretinal clinics in the Netherlands, as well as a l

19 T transformed the clinical management of the vitreoretinal conditions, iOCT has the potential to be a

20 ber congenital amaurosis (LCA) and snowflake vitreoretinal degeneration (SVD).

21 Snowflake vitreoretinal degeneration (SVD, MIM 193230) is a develo

22 och syndrome, characterized by age-dependent vitreoretinal degeneration and occipital encephalocele.

23 ings provide an explanation for high myopia, vitreoretinal degeneration and retinal detachment seen i

24 mutation can cause SVD and further show that vitreoretinal degeneration can arise through mutations i

25 Snowflake vitreoretinal degeneration should be considered in the d

26 be suspected in the setting of high myopia, vitreoretinal degeneration, and encephalocele.

27 -related, recessive RRD without any signs of vitreoretinal degeneration.

28 se-region, suggests a novel pathogenesis for vitreoretinal degeneration.

29 characterized by occipital skull defects and vitreoretinal degeneration.

30 However, distinguishing vitreoretinal diffuse large B-cell lymphoma from uveitis

31 Vitreoretinal diffuse large B-cell lymphoma is a rare di

32 trations of HGF/SF increase in proliferative vitreoretinal disease and increase in turn with increase

33 The field of vitreoretinal disease and surgery has seen tremendous gr

34 A panel of vitreoretinal disease experts was the foundation of the

35 omy allows patients who often have bilateral vitreoretinal disease to come to a stable postoperative

36 The role of HGF/SF in proliferative vitreoretinal disease was investigated.

37 plana vitrectomy surgery and the underlying vitreoretinal disease will allow the surgeon to address

38 y (OCT) has improved the care of adults with vitreoretinal disease, and OCT angiography (OCTA) is dem

39 Although PPV is a standard treatment for vitreoretinal disease, concerns exist about its long-ter

40 control group (>50 years of age) without any vitreoretinal disease.

41 recting corneal astigmatism in patients with vitreoretinal diseases and cataract.

42 screening OCT was performed, evaluating for vitreoretinal diseases including an epiretinal membrane,

43 GFAP levels are associated with a variety of vitreoretinal diseases, future studies evaluating its us

44 ent data on the economics of telemedicine in vitreoretinal diseases.

45 g the cost-effectiveness of telemedicine for vitreoretinal diseases.

46 emselves as specializing in the treatment of vitreoretinal diseases.

47 s review is to examine the macroeconomics of vitreoretinal diseases.

48 nvolved in the pathogenesis of PDR and other vitreoretinal diseases.

49 approach to the surgical management of this vitreoretinal disorder.

50 wngrowth, iridocorneal endothelial syndrome, vitreoretinal disorders, and penetrating keratoplasty.

51 wn to be present and active in proliferative vitreoretinal disorders, suggesting that Muller cells re

52 ity of Muller cells and its association with vitreoretinal disorders, we examined morphology, propaga

53 al tissue elastic modulus may have a role in vitreoretinal disorders.

54 PVD) is involved in the pathogenesis of many vitreoretinal disorders.

55 ular developmental defects, including severe vitreoretinal dysplasia, optic nerve hypoplasia, persist

56 These results indicate that early bilateral vitreoretinal eye pathology coupled with skeletal fragil

57 Fellowship-trained vitreoretinal faculty at Accreditation Council for Gradu

58 In all cases, the primary surgeon was a vitreoretinal fellow.

59 tinal breaks and RD following primary PPV by vitreoretinal fellows is low and comparable to that of f

60 Vitreoretinal fellows perform variably few pneumatic ret

61 Vitreoretinal fellows performed a variable number of PR,

62 private equity-owned practice, and 81.4% of vitreoretinal fellows voiced concerns about autonomy and

63 2 other graders that included 2 residents, 6 vitreoretinal fellows, and 4 vitreoretinal attending phy

64 plana vitrectomy (PPV) is often performed by vitreoretinal fellows.

65 , P = .32), but men were more likely to seek vitreoretinal fellowships (30% vs 11%, P < .001) and wom

66 Agreement between image graders for all vitreoretinal findings was 91% (kappa = 0.86; 95% confid

67 o masked, trained graders analyzed right-eye vitreoretinal findings, including semiautomated quantifi

68 morbidities, presenting symptoms and vision, vitreoretinal findings, treatment regimens, culture data

69 tcomes were worse for patients who underwent vitreoretinal follow-up surgery, likely because of mecha

70 B-scan sensitivity was particularly low for vitreoretinal incarceration (11%), RT (32%), and RD (78%

71 l detachment (RD), choroidal detachment, and vitreoretinal incarceration.

72 e also found in the ipsilateral vitreous and vitreoretinal interface (but not destructive chorioretin

73 of the major NO metabolite, nitrate, at the vitreoretinal interface (VRI) of normal and aged rat mod

74 The en face SS OCTA 12 x 12-mm vitreoretinal interface (VRI) slab images showed NV at b

75 hether an association between changes at the vitreoretinal interface (VRI), in particular traction (V

76 78.32 um vs 54.68 39.03 um) and frequency of vitreoretinal interface abnormalities (VIA) (2 vs 13), r

77 OCT or TD-OCT have similar ability to assess vitreoretinal interface abnormalities and outcomes of en

78 (OCT) protocol designed to evaluate formally vitreoretinal interface abnormalities on scans obtained

79 Eyes with vitreoretinal interface abnormalities or that had underg

80 (CST), subretinal fluid, intraretinal fluid, vitreoretinal interface abnormalities, disorganization o

81 It documented vitreoretinal interface abnormalities, including interna

82 There was no apparent damage of the vitreoretinal interface after unsuccessful pharmacologic

83 ght into the range of retinal defects at the vitreoretinal interface and fovea, which is not only use

84 ectral-domain OCT and en face imaging at the vitreoretinal interface and sometimes correlated with ar

85 use of rhegmatogenous retinal detachment and vitreoretinal interface disorders, as well as potential

86 Quantitative and morphologic vitreoretinal interface features were assessed reproduci

87 image modification process that enhances the vitreoretinal interface first and then the choroid, whil

88 ides wide-field 3-dimensional information of vitreoretinal interface in diabetic eyes.

89 The peculiar features noted at the vitreoretinal interface included vitreous attachment at

90 ponding well-defined vascular complex on the vitreoretinal interface on OCTA in MacTel patients was c

91 trials, and can facilitate identification of vitreoretinal interface pathology during care of individ

92 methods can provide a good assessment of the vitreoretinal interface state.

93 puter simulation ranged from 3-16 kPa at the vitreoretinal interface through a cycle of shaking.

94 ormation in SBS, revealing a wide variety of vitreoretinal interface, inner, and outer retinal change

95 The vitreoretinal interface, which often consisted of lamell

96 tween hyperreflective spaces anterior to the vitreoretinal interface.

97 t fibronectin and laminin, components of the vitreoretinal interface.

98 thin the retina and is accentuated along the vitreoretinal interface.

99 a vascular membrane owing to the ERNM at the vitreoretinal interface.

100 societal cost perspective associated with a vitreoretinal intervention.

101 Vitreoretinal interventions account for only a small por

102 Vitreoretinal interventions are generally cost-effective

103 Most vitreoretinal interventions are very cost effective usin

104 arative effectiveness and cost-effectiveness vitreoretinal interventions assessed in the US healthcar

105 Most vitreoretinal interventions confer considerable patient

106 The majority of vitreoretinal interventions confer considerable value an

107 Vitreoretinal interventions have good to excellent compa

108 The average cost-utility of these vitreoretinal interventions is US$23 026/QALY (SD US$24

109 , and cost-utility analyses encompassing the vitreoretinal interventions of the following: (1) laser

110 est that ophthalmic interventions, including vitreoretinal interventions, are cost effective.

111 tive effectiveness and cost-effectiveness of vitreoretinal interventions, measured in quality-adjuste

112 ure was spent on ocular diseases and 0.3% on vitreoretinal interventions.

113 ngly used to study the cost-effectiveness of vitreoretinal interventions.

114 cine and its impact, or potential impact, on vitreoretinal interventions.

115 Not all lymphomas with vitreoretinal involvement represent primary intraocular

116 in the incidence of SO between glaucoma and vitreoretinal IOS, based on low-certainty evidence.

117 extracellular proteins that characterize the vitreoretinal junction (fibronectin, laminin) and vitreo

118 ent comparative effectiveness studies in the vitreoretinal literature.

119 associated with overall survival in primary vitreoretinal lymphoma (PVRL) and ocular adnexal (OA)-uv

120 The best treatment option for primary vitreoretinal lymphoma (PVRL) without signs of central n

121 assessed the frequency of MYD88 mutations in vitreoretinal lymphoma (VRL) and their diagnostic potent

122 udy included 17 diffuse large B-cell primary vitreoretinal lymphoma and 12 uveitis patients.

123 ith biopsy-confirmed or clinically diagnosed vitreoretinal lymphoma and 3 eyes of 3 patients with bio

124 maging and ultimately diagnosed with primary vitreoretinal lymphoma and/or primary central nervous sy

125 The diagnosis of primary vitreoretinal lymphoma and/or primary central nervous sy

126 s and management of patients presenting with vitreoretinal lymphoma between January 1, 2020 and Decem

127 ith biopsy-confirmed or clinically diagnosed vitreoretinal lymphoma but not identified in any of the

128 opathy, can precede the diagnosis of primary vitreoretinal lymphoma or primary central nervous system

129 9 months, there was no clinical evidence of vitreoretinal lymphoma recurrence in the 7 eyes with no

130 Vitreoretinal lymphoma remains a clinical diagnostic cha

131 icroRNA-197, and microRNA-132 in the primary vitreoretinal lymphoma vitreous and higher microRNA-155,

132 Vitreoretinal lymphoma was associated with central nervo

133 had no history of lymphoma; the diagnosis of vitreoretinal lymphoma was followed by DLBCL after a lym

134 on in systemic lymphoma, mimicking a primary vitreoretinal lymphoma, is extremely rare.

135 other white dot syndromes, syphilis, primary vitreoretinal lymphoma, myopic degeneration, and central

136 Selected samples (primary vitreoretinal lymphoma, n = 3; uveitis, n = 3) were arra

137 luation in all patients with newly diagnosed vitreoretinal lymphoma.

138 kines are promising diagnostic biomarkers of vitreoretinal lymphoma.

139 years; median age, 64 years) diagnosed with vitreoretinal lymphoma.

140 standard, for the early diagnosis of primary vitreoretinal lymphoma.

141 prognosis is particularly poor compared with vitreoretinal lymphomas even in response to chemotherapy

142 After completing all vitreoretinal maneuvers including endocautery to bleeder

143 The vitreoretinal manifestations include anterior uveitis, v

144 6 highly attended annual national vitreoretinal meetings from 2015 to 2019 (30 total meeti

145 e-fourth of the main podium faculty roles at vitreoretinal meetings included for analysis over a 5-ye

146 LRDI has not been applied to vitreoretinal ophthalmological problems previously.

147 Fifteen centers with both pediatric and vitreoretinal ophthalmologists participating in level 3

148 and in retrospect using our register of the Vitreoretinal Pathology Unit.

149 ccuracy for VH, but, for every other type of vitreoretinal pathology, there were significant false po

150 ed macular degeneration (AMD), without other vitreoretinal pathology.

151 The vitreoretinal pharmacokinetic profiles were similar betw

152 f culture-proven endophthalmitis in a single vitreoretinal practice over the course of 3 years and de

153 Vitreoretinal practice patterns changed significantly fr

154 ries at a single tertiary referral pediatric vitreoretinal practice.

155 ctive single-center case series at a private vitreoretinal practice.

156 DESIGN, SETTING, AND PARTICIPANTS: Vitreoretinal practices from 17 institutions throughout

157 year period (October 2008-April 2019) from 4 vitreoretinal practices were included.

158 CLINICAL RELEVANCE: To analyze vitreoretinal procedural trends, which may indicate stan

159 To analyze vitreoretinal procedural trends, which may indicate stan

160 identify the number of allowed services for vitreoretinal procedures and commonly used pharmacologic

161 his study was to identify changes in use for vitreoretinal procedures by measuring the number of allo

162 Vitreoretinal procedures grew 6-fold from 2000 to 2014.

163 itreal injections accounted for 0.55% of all vitreoretinal procedures in 2000 and increased to 87% in

164 e and 24 (37.5%) patients who had endoscopic vitreoretinal procedures initially before undergoing a c

165 Data from 374 eyes undergoing vitreoretinal procedures were included in our study (mea

166 been used successfully, temporarily, during vitreoretinal procedures.

167 nterior segment surgeons, with postoperative vitreoretinal referral at the surgeon's discretion.

168 cle highlights some of the current trends in vitreoretinal research that promise to be revolutionary

169 Based on recent advances in ongoing vitreoretinal research, the spectrum of treatable retina

170 OCT facilitates the detection of early vitreoretinal separation that indicates initial PVD.

171 fied as partial PVD on 16.5-mm scans because vitreoretinal separation was localized to the mid periph

172 which ten centers in India with established vitreoretinal services for over 10 years were invited to

173 negotiations between representatives of the Vitreoretinal Society of India (VRSI) and India's Centra

174 aterality of FH were recorded by 1 pediatric vitreoretinal specialist.

175 Fellowship-trained vitreoretinal specialists clinically managed all patient

176 eolysis were reported in 15 patients by 7 US vitreoretinal specialists during the study period.

177 Expedited referral to vitreoretinal specialists is recommended for management

178 inopathy, two conditions commonly treated by vitreoretinal specialists, are projected to affect more

179 as a useful cutoff for guiding referral to a vitreoretinal surgeon after primary globe closure.

180 er diabetic vitrectomy, and subsequently the vitreoretinal surgeon attempted to spare the lens.

181 ced echographer and reviewed by the managing vitreoretinal surgeon for the presence of vitreous hemor

182 The vitreoretinal surgeon may consider rendering an eye nonp

183 Evaluation by a vitreoretinal surgeon should be considered for all patie

184 Automatic perioperative evaluation by a vitreoretinal surgeon was associated with a higher rate

185 sectional, 2-arm study of a single pediatric vitreoretinal surgeon's patients from a quaternary refer

186 t could provide enhanced information for the vitreoretinal surgeon.

187 th repaired and managed postoperatively by a vitreoretinal surgeon.

188 ickness macular holes (MHs) is important for vitreoretinal surgeons and their patients.

189 A random sample of 20 vitreoretinal surgeons distributed evenly among the acad

190 Current academic vitreoretinal surgeons have high mean RCR values relativ

191 There remains no consensus among vitreoretinal surgeons regarding the optimal management

192 In general, vitreoretinal surgeons should thoroughly question the ne

193 This may enable vitreoretinal surgeons to benchmark their case-mix and o

194 These results may help vitreoretinal surgeons to benchmark their intraoperative

195 Academic vitreoretinal surgeons were individually indexed using t

196 ertaken by specialized ocular oncologists or vitreoretinal surgeons with experience in managing this

197 experts (3 pediatric ophthalmologists and 6 vitreoretinal surgeons) participated in the study.

198 Load Index[SURG-TLX] questionnaire) of three Vitreoretinal surgeons.

199 lar surgeries, including cataract surgeries, vitreoretinal surgeries, and IVI, from January 2010 to D

200 reoretinopathy (PVR) is a serious problem in vitreoretinal surgeries.

201 56), specializing in glaucoma (27%, n = 16), vitreoretinal surgery (22%, n = 13), and cornea (22%, n

202 oportion of men reported primary practice in vitreoretinal surgery (47.2% vs 22.0%, P < .0001).

203 The comparison between BCVA before vitreoretinal surgery (median, 1.8 logarithm of the mini

204 entified in the fields of glaucoma (n = 12), vitreoretinal surgery (n = 5), cataract (n = 19), and co

205 nt literature on simulator-based training in vitreoretinal surgery (VRS).

206 an be achieved for most patients who undergo vitreoretinal surgery after open globe trauma.

207 Adverse events were associated with vitreoretinal surgery and immunosuppression.

208 The median time between vitreoretinal surgery and orbital emphysema was 8 days (

209 Exclusions included prior vitreoretinal surgery before cataract removal and follow

210 e predictability in patients with a previous vitreoretinal surgery can be as good as in uncomplicated

211 The role of iOCT in vitreoretinal surgery continues to be defined by active

212 targeting senior ophthalmology residents and vitreoretinal surgery fellows across Saudi Arabia.

213 Second-year U.S. vitreoretinal surgery fellows in two-year training progr

214 A total of 20 of 739 eyes (2.7%) underwent vitreoretinal surgery for complications arising from cho

215 patients who subsequently required secondary vitreoretinal surgery for complications arising from suc

216 All patients who underwent vitreoretinal surgery for complications secondary to PSC

217 Inc, Irvine, CA) can improve the outcomes of vitreoretinal surgery for established proliferative vitr

218 review of consecutive patients who underwent vitreoretinal surgery for myopic traction maculopathy by

219 Only 2 eyes required vitreoretinal surgery for nonclearing vitreous hemorrhag

220 consecutive series of patients who underwent vitreoretinal surgery for primary rhegmatogenous ARD was

221 Patients who underwent vitreoretinal surgery had overall worse visual outcomes.

222 f 360 patients undergoing 27-gauge PPV for a vitreoretinal surgery indication.

223 Eyes undergoing 27 gauge PPV for a vitreoretinal surgery indication.

224 However, Cibis' contributions to vitreoretinal surgery only occupied the last 10 years of

225 Eyes with prior vitreoretinal surgery or laser or anti-vascular endothel

226 erative sickle retinopathy were managed with vitreoretinal surgery over a 12-year period at a single

227 l of 565 eyes were included in this study of vitreoretinal surgery performed from April 2011 to June

228 Previous vitreoretinal surgery was a risk factor for failure.

229 Fifty-eyes of 50 adults undergoing vitreoretinal surgery were enrolled.

230 1.5-8.4; P = 0.0100), and eyes with previous vitreoretinal surgery were less likely to undergo succes

231 Patients who underwent vitreoretinal surgery were randomized into 3 groups base

232 rom 13 sites where data on both cataract and vitreoretinal surgery were recorded on the same electron

233 The indications for vitreoretinal surgery were recorded, as were the locatio

234 ous hemorrhage due to PDR undergoing primary vitreoretinal surgery were screened.

235 Patients with orbital emphysema after vitreoretinal surgery who were diagnosed and treated bet

236 n the US and 96% completed a fellowship (25% vitreoretinal surgery, 22% cornea and external disease,

237 ta recorded included phakic status, previous vitreoretinal surgery, and anterior chamber (AC) cells a

238 adjunct for clinical decision making during vitreoretinal surgery, and OCT angiography (OCTA) has pr

239 retinal detachment other than RRD, previous vitreoretinal surgery, and proliferative diabetic retino

240 ative optical coherence tomography (iOCT) in vitreoretinal surgery, assess the current state-of-the a

241 a constitutes a very unusual complication of vitreoretinal surgery, it is important to identify this

242 Despite significant advances in vitreoretinal surgery, it still remains without an effec

243 ing factors such as pseudoexfoliation, prior vitreoretinal surgery, or trauma.

244 t, we describe a rare case of TPSS following vitreoretinal surgery, presenting as hemorrhagic retinal

245 nine green, which is widely used as a dye in vitreoretinal surgery, spontaneously accumulate on colla

246 and 0.5% bupivacaine in patients undergoing vitreoretinal surgery.

247 its role in the modern era of microincision vitreoretinal surgery.

248 issociated) light, is redefining its role in vitreoretinal surgery.

249 1911-1965) was one of the pioneers of modern vitreoretinal surgery.

250 rful tool to capture cone regeneration after vitreoretinal surgery.

251 xpanding the scope and improving outcomes in vitreoretinal surgery.

252 c for evaluating quality of surgical care in vitreoretinal surgery.

253 esenting with posterior PFV received complex vitreoretinal surgery.

254 rful tool to capture cone regeneration after vitreoretinal surgery.

255 5 (50%) with poor prognosis did not undergo vitreoretinal surgery.

256 nade agents are crucial surgical adjuncts in vitreoretinal surgery.

257 nometry are in excellent agreement following vitreoretinal surgery.

258 was recovered from 47 individuals undergoing vitreoretinal surgery: 16 had nonproliferative diabetic

259 Numerous vitreoretinal surgical conditions and procedures have be

260 h removal of silicone oil without additional vitreoretinal surgical intervention at 6 months.

261 continued performance of urgent or emergent vitreoretinal surgical procedures, the frequency of such

262 Vitreoretinal surgical repair for this condition is succ

263 Continuous refinements in vitreoretinal surgical techniques and an increasing numb

264 Vitreoretinal surgical techniques for the management of

265 With advances in vitreoretinal surgical techniques, however, the indicati

266 With proper vitreoretinal surgical techniques, posteriorly dislocate

267 ll further expand the horizon of iOCT in the vitreoretinal surgical theater.

268 Vitreoretinal symptoms of DLBCL in patients with systemi

269 Modified vitreoretinal techniques also have been developed, allow

270 s not unusual to require relatively advanced vitreoretinal techniques to achieve long-term surgical s

271 omitantly with more experience using various vitreoretinal techniques to manage these complicated cas

272 eral granulomas (57.1%), vasculitis (57.1%), vitreoretinal traction (57.1%), and chronic macular edem

273 Previous studies have suggested that vitreoretinal traction (VRT) may contribute to the progr

274 ariant form of SNIFR driven by midperipheral vitreoretinal traction and associated with significant v

275 mulation model was developed to evaluate the vitreoretinal traction and determine whether the distrib

276 pithelium include typical findings of peaked vitreoretinal traction and retinal disorganization with

277 estive of progressive ERM contracture and/or vitreoretinal traction as compared with eyes without ILM

278 hes a new reproducible technique to quantify vitreoretinal traction during vitrectomy and demonstrate

279 It has been postulated that vitreoretinal traction plays a major role in the retinal

280 Vitreoretinal traction was found in 39 eyes (40%).

281 d macular edema, central serous retinopathy, vitreoretinal traction, and age-related macular degenera

282 and include retinal flattening, reduction of vitreoretinal traction, freeing of visual axis, and aest

283 c traction maculopathy, epiretinal membrane, vitreoretinal traction, optic or scleral pit, or advance

284 ing into zone III (p = 0.023) and associated vitreoretinal trauma (p = 0.008).

285 posterior to rectus insertion and associated vitreoretinal trauma can adversely affect the outcome in

286 erative diabetic retinopathy at 16 different vitreoretinal units in the United Kingdom.

287 ncluded in the trial were patients from 4 UK vitreoretinal units who had fovea-involving SMH of at le

288 BRI or VEH was administered by gavage, and vitreoretinal vascular endothelial growth factor (VEGF)

289 findings, retinal ganglion cell (RGC) count, vitreoretinal vascular endothelial growth factor (VEGF)

290 BRI produced marked decreases in vitreoretinal VEGF and inhibition of BRB breakdown in di

291 of ischemia responsible for upregulation of vitreoretinal VEGF and thus reduce vascular leakage and

292 sure to high oxygen significantly attenuated vitreoretinal VEGF concentrations, retinal vascular leak

293 BRI treatment significantly attenuated vitreoretinal VEGF concentrations, retinal vascular leak

294 diabetic animals but significantly decreased vitreoretinal VEGF expression and BRB breakdown to level

295 tic rats demonstrated significantly elevated vitreoretinal VEGF expression, vitreal glutamate concent

296 for all), despite negligible differences in vitreoretinal VEGF levels at the time of evaluation (P >

297 atment also significantly decreased elevated vitreoretinal VEGF protein levels and retinal BRB leakag

298 retinopathy with neurodegeneration, elevated vitreoretinal VEGF protein levels, and increased BRB bre

299 Vitreoretinal VEGF protein, vitreal glutamate, and BRB b

300 registers maintained in the laser rooms and vitreoretinal (VR) operating theatres (including paediat